
Cecile Mather
Advertisement
Articles by Cecile Mather



24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study
BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Erika P. Hamilton, MD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath Jeselsohn,Pamela N. Munster, MD,Haolan Lu,Richard Gedrich,Cecile Mather,Janaki Parameswaran,Hyo S Han
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Obesity and Cancer Risk: The Evolving Role of GLP-1s in Oncology
2
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
3
EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC
4
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
5
